Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19


Weight change, obesity and risk of prostate cancer progression among men with clinically localized prostate cancer.

Dickerman BA, Ahearn TU, Giovannucci E, Stampfer MJ, Nguyen PL, Mucci LA, Wilson KM.

Int J Cancer. 2017 Sep 1;141(5):933-944. doi: 10.1002/ijc.30803. Epub 2017 Jun 8.


Current prostate cancer treatment: Not what but when?

Massaro PA, Cagiannos I.

Can Urol Assoc J. 2016 Aug;10(7-8):251-252. No abstract available.


Stratification of brachytherapy-treated intermediate-risk prostate cancer patients into favorable and unfavorable cohorts.

Merrick GS, Butler WM, Galbreath RW, Fiano R, Adamovich E.

J Contemp Brachytherapy. 2015 Dec;7(6):430-6. doi: 10.5114/jcb.2015.56763. Epub 2015 Dec 30.


Retreatment for prostate cancer with stereotactic body radiation therapy (SBRT): Feasible or foolhardy?

Arcangeli S, Agolli L, Donato V.

Rep Pract Oncol Radiother. 2015 Nov-Dec;20(6):425-9. doi: 10.1016/j.rpor.2014.08.001. Epub 2014 Sep 10. Review.


Selenium supplementation and prostate cancer mortality.

Kenfield SA, Van Blarigan EL, DuPre N, Stampfer MJ, L Giovannucci E, Chan JM.

J Natl Cancer Inst. 2014 Dec 12;107(1):360. doi: 10.1093/jnci/dju360. Print 2015 Jan.


Metformin is not associated with improved biochemical free survival or cause-specific survival in men with prostate cancer treated with permanent interstitial brachytherapy.

Taira AV, Merrick GS, Galbreath RW, Morris M, Butler WM, Adamovich E.

J Contemp Brachytherapy. 2014 Oct;6(3):254-61. doi: 10.5114/jcb.2014.45757. Epub 2014 Oct 6.


Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus 'X'.

Ahmed KA, Davis BJ, Mynderse LA, Slezak JM, Bergstralh EJ, Wilson TM, Choo CR.

Radiat Oncol. 2014 Jul 29;9:171. doi: 10.1186/1748-717X-9-171.


Time to failure after definitive therapy for prostate cancer: implications for importance of aggressive local treatment.

Taira AV, Merrick GS, Butler WM, Galbreath RW, Fiano R, Wallner KE, Adamovich E.

J Contemp Brachytherapy. 2013 Dec;5(4):215-21. doi: 10.5114/jcb.2013.39210. Epub 2013 Dec 3.


Management of patients with biochemical recurrence after local therapy for prostate cancer.

Paller CJ, Antonarakis ES, Eisenberger MA, Carducci MA.

Hematol Oncol Clin North Am. 2013 Dec;27(6):1205-19, viii. doi: 10.1016/j.hoc.2013.08.005. Epub 2013 Sep 18. Review.


Permanent 125I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence.

Mazeron R, Bajard A, Montbarbon X, Gassa F, Malet C, Rocher F, Clippe S, Bringeon G, Desmettre O, Pommier P.

Radiat Oncol. 2012 Mar 26;7:46. doi: 10.1186/1748-717X-7-46.


Milk and dairy consumption among men with prostate cancer and risk of metastases and prostate cancer death.

Pettersson A, Kasperzyk JL, Kenfield SA, Richman EL, Chan JM, Willett WC, Stampfer MJ, Mucci LA, Giovannucci EL.

Cancer Epidemiol Biomarkers Prev. 2012 Mar;21(3):428-36. doi: 10.1158/1055-9965.EPI-11-1004. Epub 2012 Feb 7.


The basis for monitoring strategies in clinical guidelines: a case study of prostate-specific antigen for monitoring in prostate cancer.

Dinnes J, Hewison J, Altman DG, Deeks JJ.

CMAJ. 2012 Feb 7;184(2):169-77. doi: 10.1503/cmaj.110600. Epub 2011 Dec 12.


Smoking and prostate cancer survival and recurrence.

Kenfield SA, Stampfer MJ, Chan JM, Giovannucci E.

JAMA. 2011 Jun 22;305(24):2548-55. doi: 10.1001/jama.2011.879.


Long-term outcomes for patients with prostate cancer having intermediate and high-risk disease, treated with combination external beam irradiation and brachytherapy.

Dattoli M, Wallner K, True L, Bostwick D, Cash J, Sorace R.

J Oncol. 2010;2010. pii: 471375. doi: 10.1155/2010/471375. Epub 2010 Aug 18.


The current role of imaging for prostate brachytherapy.

Carey B, Swift S.

Cancer Imaging. 2007 Feb 28;7:27-33. Review.

Supplemental Content

Support Center